As the Democratic Republic of Congo grapples with a burgeoning Ebola outbreak, health experts are intensifying efforts to create three new vaccines targeting the Bundibugyo strain of the virus. The International Aids Vaccine Initiative (IAVI), along with researchers from the University of Oxford and Moderna, are at the forefront of this urgent initiative. With nearly 250 fatalities reported and over 1,000 suspected cases, the situation is prompting fears that this outbreak could mirror the catastrophic epidemic experienced in West Africa from 2014 to 2016.
Rising Threat in the Heart of Africa
The latest outbreak was first identified in a conflict-stricken region of the DRC, where healthcare resources are severely limited. This has led to widespread concern among public health officials, as the virus’s potential for rapid transmission is exacerbated by the ongoing instability. The situation is particularly alarming given that nine confirmed cases have also been reported in Uganda, highlighting the risks of cross-border spread.
Dr Mark Feinberg, chief executive of IAVI, emphasised the gravity of the situation, stating, “This is clearly threatening to be as severe an outbreak as that, if not even worse.” He noted that the immediate development of vaccines and other interventions is of utmost priority. This sentiment is echoed by Médecins Sans Frontières (MSF), which has described the outbreak as “deeply alarming,” marking a record number of cases emerging within such a short timeframe.
The Race for Vaccine Development
Vaccination efforts for Ebola are complicated by the existence of multiple virus species. While a vaccine for the prevalent Zaire strain is already in use, the current outbreak is caused by the Bundibugyo variant, which has only surfaced on two previous occasions and lacks an approved vaccine. IAVI is developing a modified version of the Zaire vaccine, which has shown promising results in preclinical trials with monkeys, achieving nearly complete protection. However, Feinberg cautions that the timeline for clinical trials remains lengthy, estimating seven to nine months, although efforts are underway to expedite this process.
In parallel, Moderna is harnessing its mRNA technology—previously deployed in the rapid development of COVID-19 vaccines—to create a candidate for the Bundibugyo strain. Stéphane Bancel, CEO of Moderna, affirmed the company’s commitment to acting swiftly and scientifically to aid in the public health response. Similarly, the University of Oxford plans to leverage its own vaccine technology, with expectations for clinical trials commencing within two to three months.
Different Approaches, Common Goal
Each of the vaccine candidates employs distinct methodologies to prime the immune system against the Bundibugyo glycoprotein, a crucial component of the virus. IAVI utilises a harmless virus engineered to include the Ebola glycoprotein, stimulating an immune response that prepares the body to combat the actual virus. Meanwhile, both the mRNA and Oxford vaccines introduce genetic instructions that prompt the creation of the glycoprotein, teaching the immune system to identify and attack it.
Despite these varied approaches, the ultimate goal remains the same: to enhance the body’s defences against Ebola. Nevertheless, differences in vaccine technologies could influence efficacy and the necessary dosage regimen, underscoring the importance of thorough testing in clinical trials.
The Role of Global Health Initiatives
The Coalition for Epidemic Preparedness Innovations (CEPI) is playing a vital role in funding these early-stage research efforts. Dr Richard Hatchett, CEO of CEPI, emphasised the urgency of the situation: “With the Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease.” The World Health Organization (WHO) has echoed these concerns, with Director-General Dr Tedros Adhanom Ghebreyesus noting that a Bundibugyo vaccine could not only help contain the current outbreak but also bolster preparedness for future health crises.
Why it Matters
The escalating Ebola outbreak in the DRC serves as a stark reminder of the vulnerabilities faced by healthcare systems in conflict zones and the urgent need for effective vaccines. The collaborative efforts of international health organisations and pharmaceutical companies highlight the importance of swift action in combating infectious diseases. As the world grapples with the lessons learned from previous epidemics, the development of these new vaccines could prove critical in not only controlling the current crisis but also in safeguarding against future outbreaks, thereby reinforcing global health security.